153 related articles for article (PubMed ID: 27713306)
21. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice.
Martínez-Moragón E; Climent M; Chiner E; Fernández-Aracil C; Sánchez-Toril F; Lluch-Tortajada I
Farm Hosp; 2019 May; 43(3):101-109. PubMed ID: 31072288
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of periacetabular osteotomy.
Sharifi E; Sharifi H; Morshed S; Bozic K; Diab M
J Bone Joint Surg Am; 2008 Jul; 90(7):1447-56. PubMed ID: 18594092
[TBL] [Abstract][Full Text] [Related]
24. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
Brown GC; Brown MM; Lieske HB; Lieske PA; Brown KS; Lane SS
Ophthalmology; 2011 Sep; 118(9):1834-43. PubMed ID: 21723614
[TBL] [Abstract][Full Text] [Related]
25. Cost-utility analysis of a medication review with follow-up service for older adults with polypharmacy in community pharmacies in Spain: the conSIGUE program.
Jódar-Sánchez F; Malet-Larrea A; Martín JJ; García-Mochón L; López Del Amo MP; Martínez-Martínez F; Gastelurrutia-Garralda MA; García-Cárdenas V; Sabater-Hernández D; Sáez-Benito L; Benrimoj SI
Pharmacoeconomics; 2015 Jun; 33(6):599-610. PubMed ID: 25774017
[TBL] [Abstract][Full Text] [Related]
26. Costs and quality of life for patients with multiple sclerosis in Belgium.
Kobelt G
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
[TBL] [Abstract][Full Text] [Related]
27. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Wade R; Grosso A; South E; Rothery C; Saramago P; Schmitt L; Wright K; Palmer S
Pharmacoeconomics; 2019 Feb; 37(2):131-139. PubMed ID: 30112635
[TBL] [Abstract][Full Text] [Related]
28. Restoring root-canal treated molars: Cost-effectiveness-analysis of direct versus indirect restorations.
Schwendicke F; Stolpe M
J Dent; 2018 Oct; 77():37-42. PubMed ID: 30006116
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Use of Filgrastim for Established Febrile Neutropenia Is Cost Effective Among Patients With Solid Tumors and Lymphomas.
Wang XJ; Tong WX; Chan A
Clin Ther; 2017 Jun; 39(6):1161-1170. PubMed ID: 28554533
[TBL] [Abstract][Full Text] [Related]
30. [Incremental cost effectiveness of multifocal cataract surgery].
Pagel N; Dick HB; Krummenauer F
Klin Monbl Augenheilkd; 2007 Feb; 224(2):101-9. PubMed ID: 17309005
[TBL] [Abstract][Full Text] [Related]
31. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.
Almutairi AR; Alkhatib NS; Oh M; Curiel-Lewandrowski C; Babiker HM; Cranmer LD; McBride A; Abraham I
JAMA Dermatol; 2019 Jan; 155(1):22-28. PubMed ID: 30477000
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
[TBL] [Abstract][Full Text] [Related]
33. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
Soini E; Joutseno J; Sumelahti ML
Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
[TBL] [Abstract][Full Text] [Related]
34. The impact of differences in EQ-5D and SF-6D utility scores on the acceptability of cost-utility ratios: results across five trial-based cost-utility studies.
Joore M; Brunenberg D; Nelemans P; Wouters E; Kuijpers P; Honig A; Willems D; de Leeuw P; Severens J; Boonen A
Value Health; 2010; 13(2):222-9. PubMed ID: 19878492
[TBL] [Abstract][Full Text] [Related]
35. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
36. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
38. Cost-utility analysis of orthoptic screening in kindergarten: a Markov model based on data from Germany.
König HH; Barry JC
Pediatrics; 2004 Feb; 113(2):e95-108. PubMed ID: 14754978
[TBL] [Abstract][Full Text] [Related]
39. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
